Crown Files to Preserve Patent Rights in India

Crown Files to Preserve Patent Rights in India 
CHAPEL HILL, NC -- (Marketwire) -- 01/23/13 --  Crown Marketing
(OTCQB: CWNM) is pleased to announce that its patent Counsel in India
has filed a Statement regarding the working of the patented invention
on a commercial scale in India in the matter of Patent No. 204009.  
Crown is committed to developing and licensing its CDDT technology in
one of the fastest growing pharmaceutical markets in the world. By
submitting this filing, Crown has preserved its patent rights in
India. 
About The Company: 
Crown's Controlled Drug Delivery Technology (CDDT) is a novel
controlled-release technology, harnessing the principles diffusion
through precise mathematical formulas. The spectrum and reliability
of pharmacokinetic profiles achievable with this technology is
superior to currently marketed formulations. Its simple design allows
for a high level of flexibility in matching chronotherapeutic
requirements. Cost-efficiencies in the commercial manufacturing
process, when compared to other drug delivery technologies, may
constitute its most important competitive advantage. 
The objective of intelligent drug delivery design amounts to
maximizing the percent of the time drug plasma levels are within the
therapeutic range and avoiding patient exposure to potentially toxic
(High) or sub-therapeutic (Low) levels.  
Crown's cost-effective application of controlled delivery
technologies will play a major role in the expansion of the
pharmaceutical, OTC and nutraceuticals industry through our ability
to improve on the performance of immediate release products in a
manner tangible to manufacturers and consumers.  
More information can be found at: www.crowncddt.com 
This release may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements contained in this release that are not historical facts
may be deemed to be forward-looking statements. Investors are
cautioned that forward-looking statements are inherently uncertain.
Actual performance and results may differ materially from that
projected or suggested herein due to certain risks and uncertainties
including, without limitation, ability to obtain financing and
regulatory and shareholder approvals for anticipated actions. 
Contact: 
Charles Van Der Ross
347-491-0565